http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005077126-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bbf869d82c271f9fc39a0d50edd4b95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94b6340521049824cf4dff90eba5222b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_968b1fc2b5bbec6078c465082071719d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2005-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7d099dab9c1816ba67ff7b2caf5d7dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4be9ae5ea8a0a0a434b067267878f94 |
| publicationDate | 2005-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2005077126-A2 |
| titleOfInvention | Use of ppargamma specific inhibitors as anti-cancer therapeutics |
| abstract | The disclosed method is directed to the use of highly selective PPARϜ inhibitors and to siRNA specific for PPARϜ for treating a patient suffering from a disease or condition characterize by excessive cell proliferation. Exemplary cancers treatable by the method of the invention include, but are not limited to, epithelial cell tumors of the lung, liver, colon, breast or prostate such as human colorectal carcinoma and hepatocellular carcinoma; and lymphocyte-based cancers such as leukemia, lymphoma and multiple myeloma. The method of the invention would be particularly useful for prevention of metastasis, e.g., of epithelial cell tumors, and for reduction in the size of primary tumors or reduction of the rate of proliferation of abnormal lymphocytes or the rate of growth of epithelial precancerous lesions, such as colon cancer polyps. The method of the invention would also be useful for treating diseases characterized by excessive tissue growth such as scleroderma, systemic sclerosis, amyloidosis and gastrointestinal stromal tumors. This treatment could also be used as an immunosuppressant, for preventing the proliferation of lymphocytes. Preferred PPARϜ inhibitors useful in the method of the invention are those that covalently bond to PPARϜ and modify its activity, e.g., by reaction of a nitrogen group in the inhibitor with a cysteine residue in the PPARϜ binding pocket. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3600353-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006099479-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2006223000-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020179534-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018183580-A1 |
| priorityDate | 2004-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 197.